-
Dream job: US soccer fans paid to watch every World Cup game
-
England left frustrated by Ghana in World Cup draw
-
Europe wilts under record heat as AC sales soar
-
Grieving Deschamps to miss France's final World Cup group game
-
Rubio rejects Iran tolls on Hormuz as deal strains multiply
-
Two-goal Ronaldo delights in silencing critics after 'attacks'
-
Cubans bid farewell to revolution hero Valdes
-
Morocco squad 'supporting' Hakimi despite impending rape trial
-
Ronaldo delights in silencing 'attacks' after making World Cup history
-
Airbus to inspect 16 A380s after cracks found on plane wings
-
'Paris in this heat is awful': Tourists change plans as sites close early
-
Bolivian government says cleared all protest roadblocks
-
'I'm back': Ronaldo scores at sixth World Cup as Portugal run riot
-
France has hottest-ever day as 'unbearable' heatwave keeps scorching Europe
-
US TV news host begs for info after kidnap note says mother is dead
-
Ronaldo double fires Portugal, England eye last 32
-
Ronaldo scores at sixth World Cup as Portugal run riot
-
Hollywood powerhouses bring AI fight to Europe
-
Portugal's Ronaldo first man to score at six World Cups
-
What is driving Europe's heatwave?
-
Rubio says US will not accept Iranian tolls on Hormuz
-
Spain's Oyarzabal happy to play through pain at World Cup
-
Marco Rubio in Gulf to reassure allies hit hard by Mideast war
-
US Supreme Court rules against man whose dreadlocks were cut off in prison
-
American Michele Kang agrees deal to buy French club Lyon
-
UN to begin evacuating stranded Mideast sailors after US-Iran talks
-
French farmers suffer arid crops, heat-stricken animals
-
Tech drags down world stocks, oil dips on supply hopes
-
Scorching heat shuts Paris landmarks early as France swelters
-
Shootout traps tourists at Rio sunrise lookout
-
Ipswich hire Gary O'Neil as manager
-
Heatwave sparks health warnings across Europe
-
Lake wins Wales captaincy race ahead of Morgan
-
Hundreds of schools close as UK braces for record-breaking heatwave
-
Tech names drag down world stocks, oil dips on supply hopes
-
Starmer vows 'orderly' transition as Labour MPs mull bid to be PM
-
Reports of Dupont inclusion in France squad 'bordering on annoying' says Galthie
-
ACTIVIST SHAREHOLDER FILES SCHEDULE 13D IN EQUUS TOTAL RETURN, INC.
-
England coach McCullum denies rift with 'good friend' Stokes
-
Europe: the world's fastest-warming continent
-
Taliban officials hold EU migration talks in Brussels
-
Gennaro Gattuso returns to coaching with Lazio after Italy debacle
-
Kenya halts US Ebola facility: health minister tells court
-
Why the heat is wreaking havoc on Europe's trains
-
Zelensky to skip key Ukraine conference in Poland over WWII row
-
Seoul leads rout for tech shares as oil prices dip
-
Europe heatwave closes schools, threatens health
-
India monsoon sweeps north but brings less rain than usual
-
Germany eyes longer working lives in pension reform plan
-
UK and markets await Burnham's economic plans
CTT Pharma's Scientists Publish Peer-Reviewed Paper in the Journal of Drug Delivery and Therapeutics
TAMPA, FL / ACCESS Newswire / December 16, 2025 / (OTCQB:CTTH) CTT Pharmaceutical Holdings, Inc. is pleased to announce that a peer-reviewed scientific paper has been published in the journal of Drug Delivery and Therapeutics, authored by our scientist Dr. Katharine Cole and Dr. Pankaj Modi, the founder of CTT Pharma. The article provides the first comprehensive scientific review describing how micellar nanotechnology, when combined with an oral dissolvable strip delivery system, can significantly improve the delivery and bioavailability of active therapeutic compounds. "This review article is an important step forward in bringing wider scientific attention to this innovative and transformative technology," said Dr. Cole.
This publication is available on the Company's website www.cttpharmaceuticals.com in the 'Scientific Publications' section. This section includes peer-reviewed articles authored by CTT scientists that contribute to the broader scientific literature in areas relevant to the company's scientific focus. These publications are provided solely for transparency and informational purposes. Additional publications will be added as they become available.
CTT Pharma
813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
A.Anderson--AT